LFCR
Lifecore Biomedical, Inc.
There isn't enough reported data to score LFCR yet.
LFCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Stable | |
| Weak |
LFCR's cash flow is currently stable, but its profitability and balance sheet are weak. There isn't enough data to rate its revenue.
LFCR PE Valuation
LFCR has no meaningful PE right now: it lost money over the past year.
LFCR Forward outlook
There aren't enough analyst estimates for LFCR to show an outlook.
LFCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.16 | +$0.11 |
| Q2 2025 | -$1.27 | -497% |
| Q1 2025 | -$1.39 | -$0.53 |
| Q4 2024 | -$0.50 | +$2.11 |
| Q3 2024 | $0.14 | +$3.56 |
| Q2 2024 | $0.32 | +$3.77 |
| Q1 2024 | -$0.86 | +$3.11 |
| Q4 2023 | -$2.61 | +$0.46 |
LFCR is still losing money, but far less than before: $1.95 per share over the past year, against $3.97 at its worst in early 2023.
LFCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.3M | -19% |
| Q2 2026 | $34.2M | -6.2% |
| Q1 2026 | $23.2M | -34% |
| Q4 2025 | $44.4M | +36% |
| Q3 2025 | $31.1M | +26% |
| Q2 2025 | $36.4M | -3.8% |
| Q1 2025 | $35.2M | -1.5% |
| Q4 2024 | $32.6M | +8% |
LFCR's revenue has slid since its 2020 peak: $25M last quarter, down 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3.5% | +6.3 points |
| Q2 2026 | 7.5% | -7.1 points |
| Q1 2026 | -20% | +5.5 points |
| Q3 2025 | -9.9% | +37 points |
| Q2 2025 | 15% | +8.9 points |
| Q1 2025 | -26% | -23 points |
| Q4 2024 | -6% | -1.1 points |
| Q3 2024 | -47% | -12 points |
LFCR's operating margin was −3.5% last quarter, down 18 points from the same quarter a year ago.
LFCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6M | +24036% |
| Q2 2026 | -$2.7M | -183% |
| Q1 2026 | $3.6M | +$7.8M |
| Q4 2025 | -$986.3K | +$7.6M |
| Q3 2025 | $25K | +$4.1M |
| Q2 2025 | $3.3M | -62% |
| Q1 2025 | -$4.3M | +$3.5M |
| Q4 2024 | -$8.6M | -$5.6M |
LFCR's free cash flow has turned positive after six years mostly in the red: $6M over the past year.
LFCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +271K shares |
| 1 year | +1.2% | +443K shares |
| 3 years | +24% | +7.4M shares |
| 5 years | +29% | +8.4M shares |
| Available history | +30% | +8.7M shares |
LFCR has 38M diluted shares, up 1.2% from a year ago.
LFCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2024 | 5,820.6x | High |
| Q3 2021 | 8.2x | High |
| Q2 2021 | 25.7x | High |
| Q4 2019 | 8.5x | High |
LFCR's net debt is more than 20 years of its operating earnings (EBITDA).
LFCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.6 | Neutral |
| Stochastic | 90.1 | Overbought |
LFCR's weekly RSI is 61 (neutral) and its Stochastic is 90 (overbought).
LFCR PE vs Healthcare Sector
| Metric | LFCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
LFCR has no meaningful PE right now: it lost money over the past year.
LFCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.2% above |
| 20 week MA | $5.21 | 23% above |
| 50 week MA | $5.85 | 9.4% above |
| 100 week MA | $6.38 | 0.3% above |
| 200 week MA | $6.45 | 0.8% below |
LFCR has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 0.8% below its 200-week average.
LFCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $10.1 | -12% |
| 2021 | $10.1 | $11.0 | +8.7% |
| 2022 | $11.0 | $6.93 | -37% |
| 2023 | $6.93 | $6.19 | -11% |
| 2024 | $6.19 | $7.28 | +18% |
| 2025 | $7.28 | $8.30 | +14% |
| 2026 YTD | $8.30 | $6.40 | -23% |
LFCR has finished lower in three of the last six years. It's down 23% so far in 2026.